Joint with: Neural Environment in Disease: Glial Responses and Neuroinflammation
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities
Jun 16–20, 2019 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage
In Person
Jun 16–20, 2019 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage
Available Formats:
Supported by the Directors' Fund
In Person
Important Deadlines
Early Registration Deadline:
April 16, 2019
Scholarship Deadline:
February 13, 2019
Global Health Award Deadline:
Deadlines not yet available for this meeting.
Short Talk Abstract Deadline:
Deadlines not yet available for this meeting.
Poster Abstract Deadline:
February 13, 2019
Meeting Summary
# Biochemistry, Structural and Cellular
# Drug Discovery, Bioengineering and Digital
# Genetics, Genomics and RNA
# Immunology
# Neurobiology
The global burden of neurodegenerative disease is staggering and growing at an alarming rate as the population ages. While Alzheimer’s disease and related dementias, as well as, Parkinson’s disease and related disorders, account for the majority of those afflicted, there are also less common but equally devastating diseases. Technical and conceptual advances are revealing disease mechanisms and providing new therapeutic opportunities. Misfolded proteins have been understood to be at the center of neurodegenerative diseases but recently there is an appreciation that these misfolded proteins may serve as seeds to template the misfolding of normal proteins, that transmission of these seeds may underlie disease progression, and that there may be different strains of these seeds with differential toxicities. Biophysical analysis of these proteins reveals a role for phase transition and liquid demixing of these intrinsically disordered proteins. Synaptic loss is an important feature of neurodegeneration which may occur long before neuronal loss, but be critically important in disease presentation and loss of function. Glia and immune activation contribute to neurodegeneration and synaptic loss, and must be understood and controlled if the disease process is to be tempered or stopped. This conference aims to address the current state of knowledge in these emerging area and to provide advanced discussion of these topics; the opportunity for interaction between scientists from different fields of research will foster new collaborations that may lead to new therapeutic opportunities to combat the coming crisis and provide medical care for those suffering from neurodegenerative diseases.
SPECIAL RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR SPONSOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
KEYSTONE SYMPOSIA THANKS OUR MEETING EXHIBITOR(S):
KEYSTONE SYMPOSIA THANKS THESE DONOR(S) FOR GENEROUSLY SUPPORTING THIS MEETING:
THESE COMPANIES HAVE GENEROUSLY AGREED TO COVER THE EXPENSES OF THEIR EMPLOYEES WHO ARE SPEAKING AT THIS MEETING:
GRANT RECOGNITION:
KEYSTONE SYMPOSIA THANKS OUR GIFT-IN-KIND MEDIA SPONSORS
Subscribe for Updates